Welcome to our dedicated page for Somalogic news (Ticker: SLGC), a resource for investors and traders seeking the latest updates and insights on Somalogic stock.
SomaLogic, Inc. (Nasdaq: SLGC) delivers cutting-edge proteomics solutions to advance disease research and diagnostic capabilities. This dedicated news center provides stakeholders with timely updates on strategic developments, financial milestones, and technological breakthroughs shaping the future of healthcare innovation.
Investors and industry professionals will find authoritative coverage of SLGC's proposed merger with Standard BioTools, quarterly earnings reports, and collaborations driving precision medicine. Our repository includes verified press releases on platform enhancements, clinical study outcomes, and executive leadership decisions.
Key focus areas span oncology, metabolic disease research, and large-scale proteomic data applications. Bookmark this page for streamlined access to SomaLogic's latest regulatory filings, partnership announcements, and peer-reviewed scientific achievements. Visit regularly to stay informed about developments impacting the diagnostics and life sciences sectors.
SomaLogic, a leader in proteomics technology, has announced it will report its financial results for the first quarter of 2023 on May 11, 2023, after market close. A conference call will follow at 4:30 p.m. Eastern Time to discuss the financial metrics and insights. Interested participants are encouraged to register online more than 15 minutes prior to the call. The company focuses on delivering actionable health-management information through its SomaScan Platform, which measures changes in proteins over time. It operates under the Nasdaq ticker SLGC and emphasizes its commitment to empowering individuals to enhance their health and wellness. The SomaScan Platform is designated for research use only and is not FDA approved.
SomaLogic reported Q4 2022 revenue of $18.8 million, representing an 18.1% decline from Q4 2021. For the full year 2022, revenue totaled $97.7 million, a 20% increase year-over-year. The company anticipates 2023 revenue between $80 million and $84 million, reflecting 12-17% growth over 2022. A management transition includes Adam Taich as interim CEO following the departure of former CEO Roy Smythe. Cash and investments stand at $539.6 million. The company is exploring strategic options, backed by a newly appointed board of directors.
SomaLogic, a leader in proteomics technology, has successfully processed 4,000 plasma samples from the China Kadoorie Biobank (CKB), delivering over 28 million data points using its 7,000-plex assay. This data will merge with genetic, lifestyle, and health outcome information to explore various research questions. The CKB study aims to uncover the genetic and environmental causes of chronic diseases among the Chinese population. The collaboration promises substantial advancements in disease understanding and risk prediction. SomaLogic's SomaScan Platform has already processed over 550,000 samples, showcasing its extensive application in proteomics research.
SomaLogic, a leader in proteomics technology, will release its financial results for the fourth quarter and full year of 2022 on March 28, 2023, after market close. A conference call with management will occur at 4:30 p.m. ET to discuss these results. Interested participants can register for the call online and access a live and archived version of the webcast on the company’s investor relations page. SomaLogic focuses on providing actionable health-management information through its SomaScan Platform, aimed at optimizing personal health via protein measurement.
